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Introduction
Cognitive dysfunction (CD) is one of  the most common of  the 19 neuropsychiatric lupus (NPSLE) syn-
dromes and manifests insidiously over time, as opposed to the more dramatic presentations of  acute con-
fusional state, stroke, and psychosis (1, 2). CD in systemic lupus erythematosus (SLE) affects multiple cog-
nitive domains, including attention, executive function, verbal and nonverbal learning, working memory, 
and psychomotor function; it is associated with significantly increased morbidity and decreased quality of  
life (3–6). The diagnosis of  CD and correct attribution to SLE-associated mechanisms rather than other 
potentially confounding factors, such as infection, metabolic disturbances, medication effects, mood dis-
turbances, and toxins, have been compromised by the poor sensitivity and specificity of  available diagnostic 
tools. Additionally, the wide variability of  CD prevalence in lupus, ranging from 3% to 80%, is ascribed to 
differences in testing metrics, subject demographics and comorbidities, and small sample sizes (7). These 
conflicting reports highlight the need for unbiased and objective assessments of, or biomarkers for, CD 
attributable to SLE that can be used for diagnosis and assessment of  response to treatment.
Proposed mechanisms for CD include chronic neurotoxic effects of  brain-reactive autoantibodies 
directed against N-methyl D aspartate receptors (cross-reactive anti-dsDNA/NMDAR antibodies, termed 
DNRAb) (8, 9), ribosomal P, and neuronal surface P antigen and direct effects of  cytokines (10–13). In a 
To address challenges in the diagnosis of cognitive dysfunction (CD) related to systemic lupus 
erythematosus–associated (SLE-associated) autoimmune mechanisms rather than confounding 
factors, we employed an integrated approach, using resting-state functional (FDG-PET) and 
structural (diffusion tensor imaging [DTI]) neuroimaging techniques and cognitive testing, in adult 
SLE patients with quiescent disease and no history of neuropsychiatric illness. We identified resting 
hypermetabolism in the sensorimotor cortex, occipital lobe, and temporal lobe of SLE subjects, 
in addition to validation of previously published resting hypermetabolism in the hippocampus, 
orbitofrontal cortex, and putamen/GP/thalamus. Regional hypermetabolism demonstrated 
abnormal interregional metabolic correlations, associated with impaired cognitive performance, 
and was stable over 15 months. DTI analyses demonstrated 4 clusters of decreased microstructural 
integrity in white matter tracts adjacent to hypermetabolic regions and significantly diminished 
connecting tracts in SLE subjects. Decreased microstructural integrity in the parahippocampal gyrus 
correlated with impaired spatial memory and increased serum titers of DNRAb, a neurotoxic autoantibody 
associated with neuropsychiatric lupus. These findings of regional hypermetabolism, associated 
with decreased microstructural integrity and poor cognitive performance and not associated 
with disease duration, disease activity, medications, or comorbid disease, suggest that this is 
a reproducible, stable marker for SLE-associated CD that may be may be used for early disease 
detection and to discriminate between groups, evaluate response to treatment strategies, or assess 
disease progression.
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murine model, DNRAb bind activated NMDARs, allowing excessive calcium influx and resulting in neu-
ronal dysfunction or death, depending on antibody concentration (14). NMDARs are located throughout 
the cortex but have highest density in the hippocampus; it has also been shown that DNRAb specifically 
target place cells in the CA-1 area of  the hippocampus, with resulting deleterious effects on spatial memory 
in mice and human disease (14, 15).
Fluorine-18 fluorodeoxyglucose PET ([18F]FDG-PET) is a functional imaging technique that mea-
sures cellular glucose uptake. Alterations in CNS glucose metabolism may reflect cell density, infection, 
inflammation, and/or abnormal cell function. We have reported previously that SLE subjects with stable 
disease activity and without known CNS disease demonstrate a pattern of  increased resting metabolism in 
the hippocampus, orbitofrontal cortex, and basal ganglia (16) that correlated with serum DNRAb titers, 
memory impairment, and mood alterations. A complementary neuroimaging technique, diffusion tensor 
imaging (DTI), is an advanced MRI technique based on the diffusion of  water molecules in tissue that 
allows for assessment of  white matter (WM) integrity and structure. Several cross-sectional studies of  DTI 
in NPSLE and SLE patients without neuropsychiatric symptoms, compared with healthy controls, suggest 
an overall decrease in WM integrity in both SLE groups (reviewed in ref. 17). However, combining imaging 
results for all NPSLE syndromes precludes the ability to evaluate individual CNS manifestations in the 
context of  proposed biologic mechanisms.
We therefore sought to continue our neuroimaging characterization of  CD in SLE and visualize struc-
tural and metabolic changes that might embody a biomarker for SLE-associated pathophysiological pro-
cesses. Based on our previously reported set of  regional metabolism changes in SLE that correlated with 
neuropsychiatric performance (16), we (a) validated those original findings in a new cohort and a larger 
combined cohort; (b) defined changes in underlying tract microstructure in the new cohort; (c) assessed lon-
gitudinal changes in brain metabolism and microstructure in these individuals; and (d) related the observed 
changes to cognitive performance and other variables, such as disease duration and serum DNRAb levels. 
We continue to focus on SLE patients with no known history of  an acute clinical NPSLE manifestation 
or other CNS event in order to avoid confounding influences from other NPSLE-related or unrelated syn-
dromes that may be driven by different underlying mechanisms.
Results
Clinical characteristics of SLE groups 1 and 2
Thirty-seven adult SLE subjects were recruited. Data from the first 17 SLE subjects (group 1 [SLE-1]) were 
published previously (16). Both groups were similar for all measured parameters, except for anti-Ro anti-
bodies, which were less frequent in SLE-1 (Table 1), and disease duration. The SLE-1 group had been strat-
ified by disease duration of  less than or equal to 2 years (n = 9) or greater than or equal to 10 years (n = 8). 
The mean disease duration in those with disease for longer than or equal to 10 years was 16.25 ± 6.78 years 
(range 10–28 years). Because regional brain hypermetabolism did not correlate with disease duration in 
our previous study (16), SLE-2 subjects were not stratified by disease duration. The mean disease duration 
for the SLE-2 group was 13.8 ± 9.19 years with a range of  2–33 years. In terms of  potential confounding 
influences on cognition, disease activity and corticosteroid doses were very low, hypertension was well con-
trolled and distributed equally between groups, coronary artery disease was rare, no subjects had diabetes, 
and smoking occurred equally between groups. The mean prednisone dose was 2.5 ± 3.4 mg, with a range 
of  0–10 mg. Based on body surface area, physiologic daily doses of  prednisone for the SLE subjects would 
range from 2.1 to 4.8 mg daily, and 84% of  them were on a daily dose of  less than or equal to 5 mg daily. 
One subject in each group had anticardiolipin antibodies, and none had a lupus anticoagulant. Clinical 
data for the 13 SLE subjects included in the longitudinal assessments at baseline (time 1 [T1]) and time 2 
(T2) are presented in Table 2. There were no significant changes in disease activity (SLEDAI scores), dam-
age (SLICC DI scores), or medication use at the times the assessments were performed. Between T1 and 
T2, 5 of  the 13 SLE subjects experienced a SLE flare requiring medication changes; 2 switched to different 
disease-modifying drugs; and 3 added disease-modifying drugs.
Cognitive and behavioral testing of SLE groups 1 and 2
There were no differences in mean throughput scores for the Automated Neuropsychological Assessment 
Metric (ANAM) subtests between the SLE groups (Table 1). However, although the SLE subjects had no 
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prior diagnosis of  cognitive impairment, in comparison with healthy control normative data (ANAM GNS 
Battery: Administration Manual and ANAM4 GNS: User Manual, Vista LifeSciences, unpublished obser-
vations), the SLE subjects demonstrated significantly lower scores on all 3 ANAM subtests (P = 0.000 for 
the Match-to-Sample and Matching Grids test and P = 0.006 for the Running Memory Continuous Perfor-
mance Test [CPT]). The Match-to-Sample subtest assesses visuospatial perception and working memory. 
89% of  the SLE subjects (82% of  SLE-1, 95% of  SLE-2, P = 0.315) scored lower than the normative mean 
for this subtest and 19% (23% of  SLE-1, 15% of  SLE-2, P = 0.68) scored less than 2 SDs below the norma-
tive mean. The Matching Grids test assesses spatial processing efficiency. 92% of  the SLE subjects (88% of  
SLE-1, 95% of  SLE-2, P = 0.584) scored lower than the normative mean for this subtest, and 41% (41% of  
SLE-1, 40% of  SLE-2, P = 1.0) scored less than 2 SDs below the normative mean. The CPT assesses vigi-
lance and sustained attention. 70% of  the SLE subjects (53% of  SLE-1, 85% of  SLE-2, P = 0.069) scored 
lower than then normative mean for this subtest, and 13% (23% of  SLE-1, 5% of  SLE-2, P = 0.159) scored 
less than 2 SDs below the mean. Both SLE groups had similar mean scores for depression and anxiety 
(Table 1); however, these did not reach cut off  points associated with clinically significant symptoms (18, 
19). The Beck Depression Inventory (BDI) has a range of  scores from 0 to 63 (18). In SLE-1, the range for 
BDI scores was 0 to 31; 13 subjects (76%) had BDI scores indicative of  no depression (BDI scores 0–13); 
Table 1. Subject characteristics for SLE-1 and SLE-2
SLE-1 (n = 17) SLE-2 (n = 20) P value
Age (yr) 37.5 ± 9.4 41 ± 10.3 0.286
Sex: female 17 (100%) 18 (90%) 0.489
Ethnicity/race
Latino/Hispanic 7 (41%) 4 (20%) 0.160
Asian 1 (6%) 1 (5%) 0.906
African American 7 (41%) 14 (70%) 0.078
White 2 (12%) 1 (5%) 0.564
Education (yr) 13.5 ± 4.3 13.3 ± 2.4 0.839
SLEDAI score 2.7 ± 2.6 2.3 ± 2.1 0.560
SLICC DI score 0.8 ± 0.8 0.9 ± 1.1 0.675
Current medications
Prednisone dose (mg) 2.4 ± 3.1 2.6 ± 3.7 0.821
Hydroxychloroquine 12 (71%) 17 (85%) 0.428
DMARDA 10 (59%) 11 (55%) 1.000
Serology
Anti-dsDNA ab+ 10 (59%) 10 (50%) 0.743
Anti-Ro+ 7 (30%) 16 (70%) 0.021
Anti-NMDAR+ 11 (65%) 9 (45%) 0.325
Anti-ribosomal P+ 2 (13%) 3 (15%) 1.000
ACL (IgG, M, or A) 1(6%) 1 (5%) 0.459
Comorbid disease
Hypertension 4 (24%) 9 (45%) 0.300
Coronary artery disease 1 (6%) 1 (5%) 1.000
Smoking: ever 4 (24%) 7 (35%) 0.495
BMI 26.5 ± 5.0 28.7 ± 5.3 0.195
Mood assessments
STAIB 35.8 ± 9.9 31.2 ± 9.1 0.151
BDI 8.9 ± 8.5 7.4 ± 5.4 0.495
ANAM testing
Match-to-Sample 21.4 ± 11.2 20.8 ± 7.2 0.834
Matching Grids 27.9 ± 10 27.1 ± 8.0 0.783
CPTC 74.2 ± 36.3 70.3 ± 17.1 0.685
ADisease-modifying anti-rheumatic drug; for SLE-1, methotrexate (n = 2), azathioprine (n = 3), mycophenolate mofetil 
(n = 5); for SLE-2, methotrexate (n = 1), azathioprine (n = 3), mycophenolate mofetil (n = 7). BState Trait Anxiety 
Inventory, evaluates current anxiety. CRunning memory continuous processing test. SLE-1, SLE group 1; SLE-2, SLE 
group 2; BDI, Beck Depression Inventory; ANAM, Automated Neuropsychological Assessment Metric.
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2 (12%) had scores indicative of  mild depression (BDI scores 14 – 19); 1 (6%) had a score indicative of  
moderate depression (BDI scores 20–28); and 1 (6%) had a score indicative of  severe depression (BDI ≥29). 
Similarly, in the SLE-2 group, the range of  BDI scores was 0 to 16; 15 (75%) had scores indicative of  no 
depression; and 5 (25%) had scores indicative of  mild depression. The range of  scores for the State Trait 
Anxiety Inventory (STAI) measure is 20–80 and a score ≥ 40 indicates increased anxiety (19). In the SLE-
1 group, the range of  scores was 20 to 52; 11 (65%) of  subjects had scores indicative of  no anxiety; and 6 
(35%) had higher scores. For SLE-2, the range of  scores was 20 to 50; 15 (75%) had scores of  less than 40; 
and 5 (25%) had scores indicative of  increased anxiety. The differences between groups for anxiety (P = 
0.719) and depression (P = 0.361) were not significant.
No significant differences were observed between T1 and T2 for the behavioral testing in the longitudi-
nal studies (Table 2). Performance on two of  the ANAM subtests, Match-to-Sample and Matching Grids, 
improved between T1 and T2 but still remained significantly below the normative mean scores.
Hypermetabolic regions identified in the combined SLE-1 and SLE-2 groups
Use of identical study methods allowed us to combine the FDG-PET data from SLE-1 and SLE-2 groups in a 
whole-brain, voxel-wise approach to compare the combined 37 SLE (SLE-1/2) and 25 healthy control (HC-1/2) 
subjects. SLE subjects demonstrated resting hypermetabolism (Figure 1 and Table 3) in the hippocampus (Fig-
ure 1, A and B; P < 0.001), orbitofrontal cortex (BA 11) (Figure 1, C and D; P < 0.002), and putamen/globus 
pallidus/thalamus (putamen/GP/thalamus) (Figure 1E; P < 0.001), the same regions originally identified in the 
SLE-1 group (16) and independently validated in the SLE-2 group (Supplemental Data and Supplemental Table 
1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.124002DS1). No 
significant differences were found between SLE-1 and SLE-2 subjects in these regions (P > 0.41). Identification 
of resting hypermetabolism in these same regions in SLE from the combined groups validates our previous 
results and, importantly, demonstrates the reproducibility and stability of the methodology.
Analysis of  the combined groups, SLE-1/2 and HC-1/2, also identified 3 new hypermetabolic regions 
(Table 3): the sensorimotor cortex (SMC) (Figure 1F; P < 0.001), occipital lobe (BA 19) (Figure 1G; P 
< 0.002), and temporal lobe (BA 37) (Figure 1H; P < 0.001). No significant metabolic differences were 
present between SLE-1 and SLE-2 subjects in these hypermetabolic regions (P > 0.10). Moreover, hyperme-
tabolism in the hippocampus and orbitofrontal cortex was highly abnormal bilaterally (P < 0.001). Hyper-
metabolism in the other 4 regions, though unilaterally abnormal at P < 0.001, was also abnormal in the 
contralateral hemisphere at a lower significance level (P < 0.005).Longitudinal analysis of  a subgroup of  13 
SLE-2 subjects with baseline and follow-up FDG-PET scans demonstrated unchanged resting hypermetab-
olism (P > 0.21) in all 6 regions over a mean of  14.9 months.
Table 2. Clinical characteristics and cognitive test results of the 13 subjects in SLE-2 with imaging at T1 
and T2, a mean of 14.9 months apart (range 11.3–19.1 months) 
T1 (n = 13) T2 (n = 13) P value
SLEDAI score 1.9 ± 1.7 3.0 ± 2.8 0.116
SLICC DI score 1.1 ± 1.1 1.4 ± 1.6 0.104
Current medications
Prednisone dose (mg) 2.9 ± 4.1 3.2 ± 3.8 0.828
Hydroxychloroquine 10 (77%) 10 (77%) 1.000
DMARDA 8 (62%) 11 (85%) 0.250
Mood assessments
STAIB 30.5 ± 9.6 33.8 ± 12.7 0.437
BDI 6.0 ± 4.5 7.5 ± 5.8 0.291
ANAM testing
Match-to-Sample 19.9 ± 7.1 23.4 ± 8.3 0.016
Matching Grids 27.0 ± 8.9 32.4 ± 11.2 0.036
CPTC 71.2 ± 20.2 74.6 ± 20.1 0.496
ADisease-modifying anti-rheumatic drug; for SLE-1, methotrexate (n = 2), azathioprine (n = 3), mycophenolate mofetil 
(n = 5); for SLE-2, methotrexate (n = 1), azathioprine (n = 3), mycophenolate mofetil (n = 7). BState Trait Anxiety 
Inventory, evaluates current anxiety. CRunning memory continuous processing test. T1, time 1; T2, time 2; BDI, Beck 
Depression Inventory; ANAM, Automated Neuropsychological Assessment Metric.
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Altered interregional metabolic relationships in SLE and functional associations
Interregional metabolic correlations were examined among the 6 hypermetabolic regions identified from 
the SLE-1/2 and HC-1/2 analyses. HC-1/2 subjects demonstrated significant interregional metabolic cor-
relations between the hippocampus and putamen/GP/thalamus (r = 0.60, P < 0.002), the hippocampus 
and temporal lobe (r = 0.40, P < 0.05), and the putamen/GP/thalamus and temporal lobe (r = 0.49, P 
< 0.02) (Figure 2A). SLE-1/2 subjects also demonstrate a significant metabolic correlation between the 
hippocampus and putamen/GP/Thalamus (r = 0.45, P < 0.006). However, other interregional metabolic 
Figure 1. Abnormal hypermetabolic regions in SLE. Top: Voxel-wise comparison of the FDG-PET scans between the combined SLE-1/2 cohorts (n = 37) 
and healthy controls (HCs; n = 25) revealed significant increases in resting glucose metabolism in SLE subjects in the hippocampus (A and B), orbitofrontal 
cortex (BA 11) (C and D), and putamen/GP/thalamus (E), the same regions independently identified in SLE-1 (1) and SLE-2 (Supplemental Data). Three new 
hypermetabolic regions identified in the SLE-1/2 subjects include the SMC (F), occipital lobe (BA 19) (G), and temporal lobe (BA 37) (H). (Peak voxel of each 
cluster was significant at P < 0.001, uncorrected. Clusters for the hippocampus, putamen/GP/thalamus, and SMC were also significant at P < 0.05, cor-
rected for cluster extent [Table 3]. Clusters were displayed using a red-yellow scale thresholded at P < 0.005 superimposed on a MRI template.). Bottom: 
Metabolism in these regions was significantly higher (P < 0.002) in the SLE-1/2 subjects (triangles) than in the healthy controls (circles) but not different 
between the SLE-1 (white triangles) and SLE-2 (black triangles) subjects (P > 0.41). (Error bar represents standard error of the mean. Arrow represents 
Student’s t test of SLE-1/2 subjects vs. HCs.)
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correlations in the SLE-1/2 subjects shift away from the temporal lobe, as seen in the HCs, to include signif-
icant correlations between the SMC and hippocampus (r = 0.38, P < 0.03) and putamen/GP/thalamus (r 
= 0.34, P < 0.04) (Figure 2B). There were no significant interregional correlations between the orbitofrontal 
cortex (HC: P > 0.07; SLE: P > 0.19) and the occipital lobe (HC: P > 0.13; SLE: P > 0.14) and any other 
hypermetabolic regions identified in SLE-1/2. These results suggest that a normal resting pattern of  inter-
regional metabolic relationships is altered among abnormal hypermetabolic regions in SLE.
Correlations between metabolic activity in the 6 hypermetabolic regions and clinical and behavioral 
measures in the SLE-1/2 subjects were also examined. Poor performance on the running memory CPT, a 
measure of  working memory and attention, correlated with increased resting metabolism in the hippocam-
pus (r = –0.35, P < 0.04), validating the previously reported relationship between these two measures (16). 
We also found new inverse correlations of  poor performance on the CPT with increased metabolism in 
other hypermetabolic areas, including the SMC (r = –0.42, P < 0.02), putamen/GP/thalamus (r = –0.32, P 
= 0.05), temporal lobe (r = –0.35, P < 0.04), and occipital lobe (r = –0.39, P < 0.02). Depression (r = 0.36, 
P < 0.03) and anger (r = 0.34, P < 0.04) on the ANAM mood scale correlated with hypermetabolism in the 
orbitofrontal cortex. Additionally, the SLICC Damage Index correlated with abnormal hypermetabolism 
in the hippocampus (r = 0.37, P < 0.03). Mean scores on the CPT test did not change significantly between 
T1 (71.2 ± 20.2) and T2 (74.6 ± 20.1) (P = 0.496) in the 13 SLE-2 subjects with repeat scans (Table 2).
Correlations of regional metabolism with disease duration
In our prior study of  SLE-1 subjects (16), decreased metabolism in the prefrontal (BA 9 and 10) and premotor 
(BA6) cortex correlated significantly with longer disease duration. In the SLE-1/2 subjects, similar inverse 
correlations with disease duration and metabolism were found in the prefrontal cortex (BA 9: r = –0.35, P < 
0.04; BA 10: r = –0.30, P = 0.07) and premotor cortex (BA 6, r = – 0.66, P < 0.0001). Among the 6 hypermet-
abolic regions in SLE-1/2, disease duration correlated only modestly with hypermetabolism in the SMC (r = 
0.33, P < 0.05). These results suggest that decreasing metabolism in the prefrontal and premotor cortices may 
be a function of  disease chronicity and damage rather than active immune–related processes.
DTI results
Microstructural changes — cross-sectional and longitudinal. Significant reductions in fractional anisotropy (FA) 
in the SLE-2 group, relative to 14 age- and sex-matched HCs (HC-3) (P < 0.001), identified 5 discrete 
regions, or clusters, with abnormal WM microstructure in the SLE-2 subjects (Figure 3 and Table 4). The 
clusters in the parietal lobe, the cingulum (hippocampus), and the splenium corpus callosum (CC) were 
significant at P < 0.001, corrected for cluster extent at P < 0.05. Cluster 1 was localized to the WM tracts 
in the parietal lobe, which is a part of  the superior longitudinal fasciculus (SLF) connecting the frontal, 
occipital, parietal, and temporal lobes. Cluster 2 was localized to the WM tracts in the vicinity of  the insu-
lar cortex, which is a part of  the uncinate fasciculus (UF), connecting parts of  the limbic system, such as 
Table 3. Brain regions with significant differences in metabolic activity between 37 SLE subjects from the combined groups 1 and 2 
(SLE-1/2) and 25 healthy controls (HC-1/2)
CoordinatesA
Brain region x y z Zmax
B HC (n = 25) SLE (n = 37)
Hippocampus Right 28 –20 –2 4.69C 1.31 (0.07)D 1.40 (0.06)F
Left –28 –24 0 4.56C 1.35 (0.07) 1.43 (0.06)F
Orbitofrontal cortex (BA 11) Right 30 40 –14 3.50 1.55 (0.07) 1.62 (0.09)E
Left –16 44 –18 3.88 1.45 (0.05) 1.52 (0.07)F
Putamen/GP/thalamus Right 30 –12 4 4.68C 1.57 (0.08) 1.66 (0.07)F
Sensorimotor cortex (BA 3/4) Right 4 –38 74 3.96C 1.47 (0.12) 1.60 (0.12)F
Occipital lobe (BA 19) Left –32 –72 8 3.45 1.20 (0.07) 1.28 (0.11)E
Temporal lobe (BA 37) Right 30 –58 –14 3.56 1.67 (0.07) 1.74 (0.07)F
AMontreal Neurological Institute standard space (60). BSignificant at P < 0.001 (peak voxel, uncorrected), SPM5 2-sample t test. CSignificant at P < 0.05, 
corrected for cluster extent, SPM5 2-sample t test. DMean (SD) regional metabolism. EP < 0.01, FP < 0.001, Student’s t test of SLE subjects vs. HC group. BA, 
Brodmann area; GP, globus pallidus; HC, healthy controls; SLE, systemic lupus erythematosus.
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the hippocampus and amygdala in the temporal lobe, with frontal lobe elements, such as the orbitofrontal 
cortex. Cluster 3 was localized to the WM tracts in the occipital lobe, which is a part of  the cingulum that is 
connected to the hippocampus and a part of  the inferior longitudinal fasciculus (ILF), which is connected 
to the temporal lobe and occipital lobe. Cluster 4 was in the WM tracts in the frontal lobe, which is a part 
of  the inferior frontal occipital fasciculus (IFOF). The last abnormal region, cluster 5, was localized in the 
WM tracts in the parietal lobe, which is a part of  the splenium of  CC. Of  note, the FA reductions observed 
in these regions were also significant (P < 0.05) in homologous areas in the contralateral brain.
To evaluate the spatial relationships of  clusters with significantly abnormal WM microstructure (low 
FA) in the SLE-2 group with corresponding hypermetabolic gray matter regions in these patients, we over-
laid statistical parametric maps of  the SLE-2 and HC-3 group contrasts, thresholded at T = 3.0 (P < 0.005) 
for metabolic activity (SLE > HC) and FA (SLE < HC) on a common MRI template (Figure 4). We found 
that 4 of  the clusters with significant SLE-related FA reductions (the SLF parietal cluster, the UF insular 
cluster, the ILF occipital cluster, the IFOF frontal cluster, see Figure 3 and Table 4) lay in close proximity to 
areas of  SLE-related hypermetabolism in the adjacent gray matter (Figure 4, yellow ellipses).
There were no significant changes in microstructural integrity FA values over a mean of  14.9 months in 
the subgroup of  13 SLE subjects with follow-up scans (P > 0.3, paired t tests) in all 5 WM regions (Table 4).
Localization of  tract changes. Each of  the abnormal FA clusters was used as a seed region for fiber track-
ing. In each pathway, fewer tracts were visualized in the SLE-2 compared with HC-3 subjects (Figure 5). 
SLE-2 subjects demonstrated reduced tract numbers in the SLF (temporal part) (−74%), the UF (−86%), 
the cingulum (hippocampus part) (−82%), the ILF (–99.5%), IFOF (–100%), and the splenium CC (−48%).
Correlations between microstructural integrity and serum DNRAb titers and spatial memory performance. As expect-
ed, performance of  SLE-2 subjects on the 2x2 spatial memory task (2x2SMT) (74%% ± 13% correct) was sig-
nificantly worse than on the 2x2 nonspatial memory task (93% ± 11% correct; P = 0.014). We examined rela-
tionships among serum DNRAb titers, 2x2SMT performance, and microstructural integrity. Serum DNRAb 
titer was entered as a covariate in a voxel-wise search for regions in which FA correlated with serum DNRAb 
Figure 2. Altered pattern of interregional metabolic correlations between abnormal hypermetabolic regions in SLE. (A) Healthy controls (HC) demon-
strate a normal pattern of interregional metabolic correlations such that resting metabolism among the hippocampus, putamen/GP/thalamus, and 
temporal lobe are all significantly correlated (filled arrows; P < 0.05). (B) In contrast, while the significant hippocampal-putamen/GP/thalamic metabolic 
relationship (P < 0.006) is preserved in SLE, other significant metabolic correlations shift away from the temporal lobe to include the SMC (P < 0.04).
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titer. A significant correlation (P < 0.002) was identified in the bilateral parahippocampal area (BA 36/BA 20, 
Figure 6A, yellow/red). Mean FA in these areas exhibited a negative correlation (r = –0.64, P < 0.002) with 
serum DNRAb titers (Figure 6B) and a positive correlation (r = 0.63, P < 0.002) with 2x2SMTscores (Figure 
6B). Moreover, a significant inverse correlation (r = –0.46, P < 0.05) was found between hypermetabolism 
in the hippocampus, identified in the FDG-PET studies of  the same SLE-2 subjects (Supplemental Table 1), 
and 2x2 SMT scores. In aggregate, these data suggest that poor performance on the spatial memory task is 
significantly associated with hippocampal hypermetabolism and decreased microstructural integrity in the 
parahippocampal region that is also associated with high serum DNRAb titers.
Discussion
We have employed an integrated approach, using resting-state functional and structural neuroimaging tech-
niques and neuropsychological testing, to characterize CD in lupus patients with quiescent, stable disease 
and no known history of  acute NPSLE or CNS dysfunction. Despite the absence of  a known diagnosis of  
NPSLE syndromes, the majority of  SLE subjects enrolled in this study scored below the mean of  healthy 
control normative data on the ANAM subtests, consistent with prior reports of  the high prevalence of  
CD in SLE (20). This is an important distinction, given the associations reported here among cognitive 
performance, abnormal brain resting metabolism, and structure. We have validated our initial findings of  
abnormal resting hypermetabolism in the hippocampus, orbitofrontal cortex, and putamen/GP/thalamus 
of  SLE subjects as well as in 3 new regions: the SMC, occipital lobe, and temporal lobe. The resting pattern 
of  interregional metabolic relationships among these hypermetabolic areas is abnormally skewed in SLE 
compared with HC subjects, and hypermetabolism in 5 of  the regions correlates significantly with impaired 
performance on a test of  working memory. Consistent with the metabolic data, FA analysis reveals 4 clus-
ters of  decreased microstructural integrity localized in WM tracts adjacent to the hypermetabolic regions, 
Figure 3. Regions with abnormal microstructure in SLE subjects. Significant reductions (P < 0.001) in FA were present in the following brain areas (top): 
1, white matter tracts in the parietal lobe, a part of the superior longitudinal fasciculus (SLF); 2, white matter tracts in the vicinity of the insular, a part of 
the uncinate fasciculus (UF); 3, white matter tracts in the occipital lobe/cingulum (hippocampus); 4, white matter tracts in the frontal lobe, a part of the 
inferior frontal occipital fasciculus (IFOF); and 5, white matter tracts in the parietal lobe, a part of the splenium of corpus callosum (CC). Individual cluster 
fractional anisotropy (FA) values for the SLE and control groups were plotted (bottom). All group differences were highly significant (P < 0.001). The details 
of these brain regions were presented in Table 4.
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and the connecting tracts are significantly diminished in the SLE subjects. Decreased microstructural integ-
rity in the parahippocampal gyrus correlates with impaired spatial memory and increased serum DNRAb 
titers. In aggregate, these results suggest that CD in SLE is characterized by a diffuse process that results in 
reproducible resting hypermetabolism in several gray matter regions and disruption of  normal resting met-
abolic patterns that associate with (a) poor performance on cognitive testing and (b) clusters of  decreased 
microstructural integrity that are connected by diminished WM tracts. While many inflammatory mole-
cules associated with SLE have the potential to damage neurons through direct neurotoxicity, microglial 
activation, or other mechanisms (10, 12, 13), it is not surprising that antibodies targeting the NMDA recep-
tor (DNRAb) are significantly associated with impaired spatial memory and abnormalities in glutamatergic 
brain regions, such as the hippocampus and parahippocampus.
There have been many studies utilizing FDG-PET imaging in SLE and a variety of NPSLE syndromes 
that, in contrast to our results, have reported regional hypometabolism in the frontal, temporal, parietal, and 
parietal-occipital regions (21–25). Regional gray matter hypermetabolism has been reported rarely in the striatal 
nuclei and basal ganglia, typically in the clinical context of SLE patients with choreoathetoid movements (23, 
26, 27). Several important differences in methodology may account for the dissimilarities with our results. Each 
of these previous studies has imaged SLE subjects with active disease, with or without NPSLE (focal deficits, 
acute confusional state, mood disorders, CD, seizures), with attendant treatment regimens, including high doses 
of glucocorticoids and immunosuppressive medications. The analyses done in these studies have been based on 
measures of glucose metabolism in prespecified regions of interest (ROIs), which were applied to each scan, 
and comparisons were either between active SLE and active NPSLE or healthy controls. Our analytic approach 
employed an unbiased, voxel-wise search of whole-brain volumes to directly compare SLE and healthy control 
subjects. This approach may have allowed for greater sensitivity and objectivity in detecting differences between 
groups than an approach that uses predetermined ROIs. Additionally, we studied SLE subjects with no history 
of active or prior CNS events, relatively few significant comorbid diseases, or high levels of antiphospholip-
id antibody titers, with low/stable disease activity, thereby avoiding confounding influences of medications, 
comorbid disease, and disease activity, whether neuropsychiatric or peripheral. The reproducibility of regional 
hypermetabolism in the hippocampus, orbitofrontal cortex, and putamen/GP/thalamus in both the separate 
and combined SLE cohorts validates the stability of our methodology and suggests that hypermetabolism rep-
resents a SLE-associated biologic process in these regions. Interestingly, several prior FDG-PET studies report-
ed follow-up scans that demonstrated improvement or normalization of the previously found hypometabolic 
regions in subjects with clinical improvement (23–25). It is therefore likely that the regional hypometabolism was 
a function of acute illness, whether a specific NPSLE syndrome or not, as it is known that many inflammatory 
Table 4. Brain regions with significant differences in FA between 14 healthy controls (HC-3) and 19 SLE-2 
subjects at baseline (TP1) and stability of FA measures in 13 SLE-2 subjects over a mean of 15 months 
from TP1 to TP2
CoordinatesA
Brain region x y z Zmax
B HC (n = 14) SLE TP1 (n 
= 19)
SLE TP2 (n 
= 13)
Parietal lobe, left, SLF –33 –35 22 4.66C 0.38 (0.03)D 0.32(0.03) 0.32 (0.03)
Insular, left, UF -36 5 –13 4.33 0.28 (0.03) 0.23(0.02) 0.22 (0.03)
Cingulum (hippocampus), 
left, ILF
–18 –69 –1 4.29C 0.32 (0.03) 0.25(0.02) 0.24 (0.02)
Frontal lobe, left, IFOF –31 33 8 4.02 0.38 (0.02) 0.34(0.02) 0.34 (0.02)
Parietal lobe, right, 
Splenium CC
17 –57 38 3.96C 0.40 (0.02) 0.32(0.06) 0.32 (0.06)
AMontreal Neurological Institute standard space (60). BSignificant at P < 0.001 (peak voxel, uncorrected), cluster extent 
test. CSignificant at P < 0.05, corrected for for cluster extent test. DMean (SD) regional fractional anisotropy (FA). In all 
5 brain regions, when comparing SLE-2 with healthy control subjects, P < 0.001, Student’s t test. FA was also assessed 
in the same clusters in 13 of the SLE-2 subjects a mean of 15 months later at TP2. When comparing FA in all 5 clusters 
from these 13 SLE-2 subjects at TP1 to TP2, P > 0.3, paired Student’s t test. HC, healthy controls; SLE, systemic lupus 
erythematosus; TP, time point; SLF, superior longitudinal fasciculus; UF, uncinate fasciculus; ILF, inferior longitudinal 
fasciculus; IFOF, inferior frontal occipital fasciculus; CC, corpus callosum. 
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molecules associated with disease flares can affect CNS function (reviewed in ref. 12). Follow-up scans in 13 of  
our SLE subjects, with low disease activity at the time of imaging, demonstrated no significant change over a 
mean of 14.9 months, despite evidence of increased interim SLE disease activity in 5 of these 13 subjects. These 
data suggest that the persistent hypermetabolism may be intrinsic to SLE and is not associated with disease dura-
tion or disease activity. This is in contrast to the hypometabolic regions in the prefrontal and premotor cortices, 
identified in all 3 SLE groups, that correlated with disease duration, suggesting an association between hypome-
tabolism and chronic damage. We hypothesize that the stability of the regional metabolic overactivity appears to 
be a reproducible, stable marker for SLE-related CD that may be responsive to targeted therapies and therefore 
potentially useful as an outcome measure in a clinical trial.
Increased PET signal indicates metabolic overactivity that may represent regional neuronal activity, 
local inflammatory or oncogenic activity, or disinhibition after damage to remote but connected regions 
(28–31). Turning to preclinical experiments for guidance, it has been demonstrated in micro–FDG-PET 
studies of  nonautoimmune mice immunized to produce serum DNRAb that affected mice have decreased 
metabolism in the hippocampus in the first 2 weeks after blood-brain barrier disruption, coincident with 
histological study of  neuronal toxicity and death. This is followed over 9 weeks by steadily increasing 
hippocampal metabolism that correlates inversely with hippocampal CA1 neuron number, verified with 
unbiased quantitative histopathology. These findings suggest a delayed tissue response  — either a com-
Figure 4. Spatial proximity of white matter regions with abnormal reductions in fractional anisotropy in SLE-2 
patients and areas of increased metabolic activity in adjacent gray matter. White matter regions with abnormal 
reductions in fractional anisotropy are represented in green (clusters 1–4, see Figure 3 and Table 4); areas of increased 
metabolic activity in adjacent gray matter are represented in red (see Figure 1 and Table 3. Adjacent gray and white 
matter regions are encompassed by yellow ellipses. (Clusters represent areas with significant differences in local 
fractional anisotropy [FA] or metabolic activity in SLE vs. healthy control subjects [thresholded at T = 3.0, P < 0.005], 
overlaid on the MNI152 T1 MRI template.).
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pensatory neuronal mechanism or an inflammatory mechanism such as recruitment of  microglial cells 
to sites of  neuronal necrosis (32). These preclinical data provide a cautionary tale in the interpretation of  
cross-sectional human data. We have identified several abnormal hypermetabolic regions in SLE that do 
not associate with age, disease duration, current medication use, or disease activity; that exhibit abnormal 
metabolic relationships between each other; and associate with poor performance on a memory task, but 
we cannot know whether the hypermetabolism is representative of  a compensatory neuronal response, 
decreased inhibitory input from another damaged region, or a microglial response to damaged neurons or 
other inflammatory molecules.
This is relevant to the shift in interregional metabolic relationships away from the temporal lobe to 
include the SMC that we report in SLE subjects. Possible explanations for this shift include damage to the 
temporal lobe, damage to the SMC with influx of  microglial cells, and compensatory neuronal response 
or damage elsewhere resulting in decreased inhibitory input to the SMC. Nonetheless, these data suggest, 
perhaps, an erosion of  normal, resting-state brain activity that characterizes SLE patients and associates 
with impaired performance on cognitive testing. Once a significant resting pattern has been identified, par-
ticularly one that is not associated with disease duration, disease activity, medications, or comorbid disease, 
it may be used for early disease detection, to discriminate between groups, to evaluate response to treatment 
strategies, or to assess disease progression.
Integration of  the PET metabolic data and the DTI structural data suggests correlations between 
regional hypermetabolism and areas of  diminished WM microstructural integrity that may account for 
the shift in interregional metabolic relationships. DTI analyses identified 4 WM clusters: the parietal lobe 
involving the SLF, the insula involving the UF, the occipital lobe involving the ILF, and the frontal lobe 
involving the IFOF. These areas of  abnormally decreased FA in WM were in close proximity to hyper-
metabolic regions in the adjacent gray matter (Figure 4, ellipses). For each of  these projection pathways, 
tractography (see Methods) revealed fewer tracts in the SLE-2 sample relative to HC-3 control subjects. 
Our interpretation of  these compelling data is that the original insult may take place in the hypermetabolic, 
gray matter regions, followed by disruption of  the WM tracts connecting them. Additional longitudinal 
studies are needed to verify this prediction. While several studies have reported WM alterations in NPSLE 
compared with HC subjects in segments of  the CC, the forceps, anterior corona radiata, thalamus, and 
parietal and frontal lobes (33–36) and overall diminished volume of  the CC (34, 37), our results support the 
Figure 5. White matter pathways associated with the abnormal SLE-related regions visualized with group tractography. The superior longitudinal 
fasciculus (temporal part) (SLF) (noted as 1), uncinate fasciculus (UF) (noted as 2), cingulum (hippocampus part) and inferior longitudinal fasciculus (ILF) 
(noted as 3), inferior frontal occipital fasciculus (IFOF) (noted as 4), and the splenium of the corpus callosum (CC) (noted as 5) pathways reconstructed in 
the healthy control (left) and SLE (right) groups. Fewer tracts were visualized in the SLE group relative to the controls in the SLF (temporal part) (−74%), 
UF (−86%), cingulum (hippocampus part) (−82%), ILF (–99.5%), IFOF (–100%), and splenium CC (−48%).
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growing body of  literature demonstrating significant WM abnormalities in SLE subjects without acute neu-
ropsychiatric manifestations (38–42). Most of  these studies in SLE subjects without neuropsychiatric man-
ifestations failed to demonstrate significant correlations between diminished WM integrity and cognition. 
However, Shapira-Lichter et al. have reported impaired performance on a learning and verbal memory task 
that correlated with decreased integrity of  WM tracts in the CC and cingulum in SLE subjects without 
neuropsychiatric symptoms (40). We have identified a significant correlation between reduced FA in the 
parahippocampal gyrus, poor performance on a spatial memory task, and elevated serum DNRAb titers. 
Poor performance on the 2x2SPMT also correlated with hippocampal hypermetabolism. These results sug-
gest the importance of  selective cognitive testing based on biologic mechanisms rather than predetermined 
cognitive batteries that may not capture the specific cognitive deficit related to a particular mechanism. The 
hippocampus, the center for memory processing and storage (43), is one of  the regions with reproducible 
hypermetabolic results that we have identified in SLE subjects. Hippocampal abnormalities have been well 
described in SLE patients and animal models. In human SLE, hippocampal atrophy, presumably reflective 
of  neuronal loss, has been correlated with cognitive deficits (38, 44–48) as well as specific autoantibodies, 
including DNRAb (44, 49). Our findings of  reproducible hippocampal hypermetabolism with functional 
correlates extend these previous reports, suggesting an SLE-mediated attack on the hippocampus. In ani-
mal models, neuronal damage and atrophy in the hippocampus in lupus mice correlates with impaired spa-
tial learning (50) that is prevented with immunosuppressive therapy (51). Selective targeting of  hippocam-
Figure 6. Microstructural integrity (FA) in the parahippocampus regions correlates with serum DNRAb titers and performance on a spatial memory test 
in SLE subjects. (A) Regression analysis of voxel-wise correlations between FA maps and serum DNRAb titers revealed a significant inverse correlation 
between FA values in the bilateral parahippocampal gyrus (BA 36/BA 20; yellow/red areas) and serum DNRAb titers. (B) Mean microstructural integrity in 
the bilateral parahippocampal gyrus exhibited a negative correlation with serum DNRAb titers (r = –0.64, P < 0.002, left). Mean microstructural integrity in 
the bilateral parahippocampal gyrus also exhibited a positive correlation with performance on a spatial memory test (r = 063, P < 0.002, right). Pearson’s 
product-moment correlation coefficient was used to evaluate the correlations between FA values and serum DNRAb titers and 2x2SMT scores.
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pal neurons by DNRAb in the mouse model, specifically place cells in the CA1 region of  the hippocampus, 
results in cognitive and spatial memory deficits (15, 52). We previously reported a significant association in 
SLE patients between serum DNRAb titers and impaired performance on the 2x2SMT (15). We currently 
report a significant correlation between performance on the 2x2SMT and hippocampus metabolism. In 
addition, identification of  correlations between reduced microstructural integrity in the parahippocampal 
gyrus and poor performance on the 2x2SMT as well as high serum DNRAb titers in SLE subjects further 
supports the hypothesis that antibody-mediated neuronal toxicity may induce damage to the hippocampal 
region that results in disorganization and reduced integrity of  the WM outflow tract through the parahip-
pocampus and manifests functionally as impaired spatial memory.
Our study is limited by the use of  historical healthy controls; although they are age- and sex-matched 
and their PET/MRI imaging protocols were identical to those used for the SLE subjects, we do not have 
cognitive testing on these individuals or information regarding ethnicity, race, and socioeconomic status. 
Additionally, the lack of  functional imaging during cognitive testing limits our interpretations to asynchro-
nous correlations between task performance and integrity of  the neuroanatomy. This was an intentional 
choice, as we are unable to ensure subject motivation during testing in a scanner; however, we acknowledge 
that functional imaging during testing would provide additional valuable information.
In summary, this is the first study to our knowledge to examine both gray and WM abnormalities together 
in SLE in concert with cognitive assessments. We have used structural and functional imaging to demonstrate 
the reproducibility of  regional resting hypermetabolism in several areas of  the brain that is unchanged over a 
mean of  14.9 months, which may represent a resting metabolic signature for intrinsic SLE-associated pathol-
ogy that correlates with CD. The associated DTI studies identified WM clusters with reduced microstructural 
integrity that were connected by significantly diminished tracts, several of  which were adjacent to the hyper-
metabolic regions. Moreover, relationships among serum DNRAb, hippocampal glucose metabolism, micro-
structural integrity in the parahippocampus, and performance on spatial memory tasks suggest that an initial 
insult occurring in gray matter may lead to decreased integrity of  WM outflow tracts, resulting in impaired 
memory function. In this case it may be DNRAb that is the inciting factor but many other inflammatory 
molecules, including IFN-α, IFN-γ, IL-1β, IL-6, and others have been implicated (10, 12, 13). Continued lon-
gitudinal studies are necessary to prove our hypothesis as are other types of  imaging studies to determine the 
contributions of  neuronal versus microglial cell activity to regional hypermetabolism. To avoid confounding 
influences on our cognitive, behavioral, and imaging outcomes, we have restricted our subject population; 
however, it will also be useful to validate our findings in SLE patients with a broader spectrum of disease 
activity to see if  changes in disease activity or medications alter the resting metabolic signature.
Methods
Study design
This is a prospective, observational study designed to evaluate associations among brain regional resting metab-
olism, microstructural integrity, serum DNRAb titers, and performance on cognitive testing in SLE subjects 
with quiescent disease and no history of CNS insult or known neuropsychological illness. Assessments were 
performed at baseline and after a mean of 15 months in the SLE subjects. Imaging studies from SLE subjects 
were compared with imaging studies from age- and sex-matched historical healthy control subjects.
Subject selection
SLE subjects in groups 1 and 2. Thirty-seven SLE subjects were recruited from the Rheumatology Clinics at 
the Feinstein Institute for Medical Research (FIMR). All were 18 years of  age or older and fulfilled Amer-
ican College of  Rheumatology revised criteria for SLE (53). FDG-PET imaging data from the first 17 SLE 
subjects (group 1; SLE-1) were published previously (16). Data from the newly recruited 20 SLE subjects 
(group 2; SLE-2), studied under the same FDG-PET imaging protocol as SLE-1, were used separately 
and in combination with those from group 1 for the validation studies. In addition to baseline FDG-PET 
imaging, SLE-2 subjects also had MRI-DTI at baseline and repeat PET and DTI studies a mean of  14.9 
(range 11.3–19.1 months) months later. To avoid confounding influences on neuroimaging and neuropsy-
chological endpoints, key exclusion criteria included the presence of  active or prior NPSLE or other CNS 
event; structural abnormalities on MRI; current use of  antidepressant, antipsychotic, or anxiolytic drugs; 
or history of  illicit drug use. Additionally, SLE subjects were required to have stable disease activity and 
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medication doses for 4 weeks prior to assessments. Group 1 recruitment was also stratified by disease dura-
tion, with presence of  disease for less than 2 or more than 10 years. As disease duration did not contribute 
to regional brain hypermetabolism (1), group 2 subjects were not stratified by disease duration.
Healthy control subjects. For FDG-PET studies, we studied 25 healthy control (HC-1/2) subjects, includ-
ing the 17 HC subjects (HC-1) in the previously published study of  the SLE-1 subjects (16) and 8 HC sub-
jects (HC-2; 2 newly recruited and 6 selected historical HCs at the Center for Neurosciences in the FIMR), 
matched for sex and age to the SLE-2 subjects. For MRI-DTI studies, 14 age- and sex-matched healthy con-
trols (HC-3) were selected from a historical cohort of  diffusion MRI studies at the FIMR. As the majority of  
HC subjects (23 of  25) were selected from an imaging historical healthy control cohort established at the Cen-
ter for Neurosciences in the FIMR, we were able to match for sex and age but not for ethnicity, race, BMI, and 
socioeconomic status even though race, BMI, and socioeconomic status have been reported to influence struc-
tural brain development (54, 55). The HC subjects also did not perform the cognitive and behavioral testing.
Assessments
Clinical, cognitive, and behavioral assessments for SLE subjects. Disease activity and accrued damage were assessed 
with the Safety of  Estrogens in Lupus Erythematosus National Assessment–SLE Disease Activity Index 
(SELENA-SLEDAI) (56) and the Systemic Lupus International Collaborating Clinics Damage Index (SLICC 
DI) (57) within 2 weeks of  imaging and cognitive assessments. CD was assessed with the ANAM (58), a 
computerized battery of  measures of  sustained attention, visual search, computational skills, concentration, 
cognitive processing, and working memory. The following ANAM subtests were selected for this study the 
Matching Grids test, a measure of  spatial processing efficiency, where two designs are shown sequentially and 
the viewer is asked to determine if  they are the same as or different from each other; the Match-to-Sample 
test, a measure of  visuospatial perception and working memory, where the subject is asked to select which 
of  two checkerboard matrix designs match a target checkerboard matrix design presented 5 seconds earlier; 
and the CPT, a measure of  vigilance and sustained attention where a running set of  numbers is presented in a 
randomized sequence. For this test, the subject is asked to continuously monitor the numbers and determine 
if  each new number is the same as or different from the preceding number (59).
Throughput scores for each ANAM subtest, representing a combination of  reaction time and accuracy, 
were the primary measure of  cognitive efficiency used in the analyses. As data for the majority of  HC sub-
jects was obtained from a historical healthy control cohort, they did not undergo cognitive and behavioral 
testing. Normative data from community and college subjects was used for comparison with the SLE sub-
ject data. We did not assign a strict cutoff  for cognitive impairment but report the percentages of  SLE sub-
jects scoring less than the normative mean or 2 SDs below the normative mean. The raw throughput scores 
for the ANAM tests were used in the analyses. SLE subjects were rated for depression and anxiety with the 
BDI (18, 60), STAI (19), and the ANAM mood domain assessments. The 2x2SMT assessed both object 
recognition and memory for spatial relations (Supplemental Figure 1) (15). All assessments were complet-
ed at baseline and repeated in 13 of  the SLE-2 subjects after a mean of  14.9 months. Four of  the SLE-2 sub-
jects withdrew from the longitudinal study, and all of  the remaining 16 SLE-2 subjects underwent follow-up 
assessments; however, both the research MRI and PET scanners at the institution were replaced during that 
time. To alleviate concerns associated with analyses of  data derived from different scanners, only follow-up 
data for 13 SLE subjects with repeat studies on the original scanners are presented here.
PET. At baseline, all 37 SLE (20 SLE-2 and 17 SLE-1) and 25 HC-1/2 subjects (men/women: 2/23, 
age 40.7 ± 12.9 years) underwent FDG-PET imaging following an overnight fast, as described elsewhere 
(61). Thirteen of  the twenty SLE-2 subjects had repeat FDG-PET scans on the same scanner 11–19 months 
from baseline (mean 14.9 months). Scanning was conducted in 3D mode using the GE Advance tomo-
graph (General Electric Medical Systems) at the FIMR. Autoradiographic PET images were acquired for 
20 minutes beginning 35 minutes after the injection of  3.5 mCi FDG in an eyes-open rest state in a dimly 
lit room with minimal auditory stimulation. FDG-PET images were preprocessed using Statistical Para-
metric Mapping (SPM5, https://www.fil.ion.ucl.ac.uk/spm/software/spm5; Institute of  Neurology, Lon-
don, United Kingdom) running in MATLAB (MathWorks), as described previously (16, 62). Baseline and 
repeat scans from the 13 SLE-2 subjects were realigned. Individual images of  all SLE and HC subjects 
were normalized and nonlinearly warped into the Talairach space using a standard PET template and then 
smoothed with an isotropic Gaussian kernel (10 mm) in all directions to improve the signal- to-noise ratio. 
Investigators were blinded to subject identity and clinical status during data acquisition and analysis.
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MRI-DTI. Nineteen of  the twenty SLE-2 subjects (men/women: 2/17, age 45.12 ± 10.58 years) and 
14 HC-3 subjects (men/women: 2/12, age 42.02 ± 10.72 years) underwent MRI in the Signa HDxt 3.0 
T scanner (GE Healthcare) at North Shore University Hospital, with an 8-channel head coil. Thirteen 
(men/women: 0/13, age 43.91 ± 9.73 years) of  the nineteen SLE-2 subjects had repeat scans a mean of  
14.9 months later. For DTI, a single-shot spin-echo echo planar imaging sequence was used with 33 dif-
fusion gradient directions and 5 B0 images. The b value in the diffusion-weighted images was 800 s/mm2. 
The FOV was 240 mm, 55 slices were acquired with 2.5-mm thickness, TE = 82.7 ms, TR = 15 seconds, 
flip angle = 90°, and scan time = 9.5 min. The 128 × 128 images were 0 filled to a matrix size 256 × 256, 
yielding an image resolution of  0.9 × 0.9 × 2.5 mm3. For high-resolution T1-weighted structural scans, the 
FOV was 240 mm, 176 slices were acquired with 1-mm thickness, the imaging matrix was 256 × 256, flip 
angle = 8°, TR = 7.6 ms, TE = 2.9 ms, inversion time = 650 ms, with resolution of  0.9 × 0.9 × 1 mm3. After 
DTI acquisition, the following DTI processing steps were performed using the FMRIB library (http://
www.fmrib.ox.ac.uk/fsl/). Diffusion-weighted images were corrected for eddy current distortions and head 
motion using the eddy current correction routine in (EDDY) (63). Nonbrain tissue was removed from the 
images using the brain extraction tool (BET2). Diffusion tensor for each brain voxel and FA map were 
determined for all subjects using DTIFIT. B0 image was registered to the Montreal Neurological Institute 
(MNI-152: 1 × 1 × 1 mm3) template using a 12-parameter affine transformation (FLIRT) (64). The resulting 
transformation was then applied to the FA map to register it to MNI space. Once aligned, the FA images 
were smoothed using a kernel of  8 mm (FWHM) for group comparison and regression analysis.
FA was chosen specifically as the optimal measure for WM structural integrity, as it reflects WM fiber 
density, axonal diameter, and myelination. Four commonly used measures of  DTI include FA, mean dif-
fusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) (65). These measures directly relate to the 
value of  the 3 eigen values (λ1, λ2, λ3) of  the tensor, with different individual properties. MD is a measure 
preferentially used to probe gray matter microstructure because gray matter tissue lacks directional diffu-
sion, whereas FA, RD, and AD are used to assess WM microstructure due to inherent directional diffusiv-
ity present in WM (66). Although AD is more specific for axonal degeneration and RD is more specific for 
demyelination, FA is highly sensitive to microstructural WM changes (65) and was therefore selected to 
assess the WM changes in SLE patients in this paper.
Statistics
Baseline characteristics of  SLE subjects and ANAM throughput scores were analyzed using Student’s t 
tests or nonparametric Mann-Whitney U tests, χ2 tests, or Fisher’s exact test, as appropriate. Relationships 
among resting regional metabolism, ANAM scores, and clinical parameters were examined using Pearson’s 
correlations. Differences between T1 and T2 for the longitudinal studies were analyzed with paired t tests 
or the Exact McNemar test. Analyses were performed using SAS9.4.
FDG-PET analysis. To prospectively validate the significant findings from group 1 (1), metabolic activity 
in each previously identified hypermetabolic region was measured for group 2 subjects (SLE-2 and HC-2) 
using spherical (radius = 5 mm) volumes of  interest (VOIs), centered at the peak voxel of  each cluster and 
normalized by dividing the global metabolic rate measured in each scan. To further assess abnormal region-
al metabolism in the SLE-2 subjects, a voxel-wise search of  whole-brain volume using the SPM5 2-sample 
t test option was performed to compare scans from the 20 SLE-2 subjects and the 25 HC-1/2. Moreover, 
nearly identical subject selection protocols for SLE-1 and SLE-2 allowed us to combine the 37 SLE-1/2 
scans and compare them with the 25 HC-1/2 scans in another voxel-wise search of  whole-brain volume 
using the SPM5 2-sample t test option. For significant regions identified in each SPM analysis, VOIs were 
used to measure regional metabolism in each of  the SLE-1/2 and HC-1/2 subjects. For both analyses, SPM 
(T) maps were created and considered significant at the threshold of  T ≥ 3.2, P < 0.001 (peak voxel, uncor-
rected). Regional metabolism was compared between the SLE-1/2 and HC-1/2 subjects or between the 
SLE-1 and SLE-2 subjects using Student’s t tests in post hoc statistical analyses following the SPM imaging 
analysis. Longitudinal changes in regional metabolism in the SLE-2 subjects were compared between base-
line and follow-up (mean 14.9 months) using paired Student’s t tests.
DTI analyses — group differences. Voxel-wise searches for microstructural differences between SLE-2 
and HC-3 groups at baseline were conducted using SPM8 software (http://www.fil.ion.ucl.ac.uk/spm/
software/spm8/). A WM mask in SPM template was applied in this analysis. The voxel-wise FA group 
contrasts were considered significant at P = 0.001 at peak voxel, corrected for cluster extent at P < 0.05. We 
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also reported regional differences at a hypothesis-testing threshold of  P < 0.001 (voxel level uncorrected), 
with a cluster cutoff  of  100 voxels. Individual FA values from each significant cluster were computed for 
each subject at the baseline and follow-up scans. The individual subject data were inspected for outliers and 
overlapping values between the groups. Group differences were evaluated post hoc using Student’s t test. 
Microstructural integrity changes over time were evaluated post hoc using paired Student’s t tests.
Tractography. Based on the assumption that the orientation of  the longest axis (v1) of  the diffusion ten-
sor represents local fiber orientation (67), 3D streamlined information from the tensor field, called tractog-
raphy, were reconstructed. This tractography method requires seeds from which streamlines are propagated 
based on v1 orientations. The streamlines are terminated when they reach a low anisotropy region where 
there is no coherent fiber organization. Voxel-based comparison of  the FA maps for SLE-2 compared with 
HC-3 subjects identified clusters with significantly reduced microstructural integrity that were used as seed 
volumes for tractography. WM pathways passing through these clusters were reconstructed separately for 
the two groups. The main purpose of  showing these group fiber tracts was to visualize WM trajectories in 
3 dimensions, particularly in relation to areas with abnormal microstructure (local FA) in the SLE brain. 
This allowed us to identify the WM pathways associated with these abnormal clusters and to evaluate 
potential disruption of  anatomical connectivity in the SLE group occurring in the vicinity of  these clusters. 
Diffusion-weighted images from subjects in each group were registered to the template; the gradient vectors 
were reoriented for tensor calculation (68, 69); and TrackVis (Massachusetts General Hospital; http://
www.trackvis.org/) was used to reconstruct and visualize the group tractography. The fiber-tracking pro-
gram (Diffusion Toolkit) takes tensor files and generates whole-brain fiber tracks saved to a track data file. 
The visualization program (TrackVis) utilizes the track data file to visualize the tracks. Tracking parameters 
were identical for the two groups. The WM mask, the angle threshold of  35, and z-inversion were set up in 
TrackVis. The reconstructed tracts were displayed for SLE-2 and HC-3.
Spatial memory test correlation. Voxel-wise correlations between FA maps and serum DNRAb titers in 
SLE-2 subjects were assessed using regression analysis in SPM8 software. The voxel-wise contrasts were 
considered significant at a hypothesis-testing threshold of  P < 0.001 (voxel level uncorrected), with a cluster 
cutoff  of  100 voxels. Individual FA values from each significant cluster were computed for each subject. 
Correlations between these FA values, serum DNRAb titers, and 2x2SMT scores were evaluated post hoc 
using Pearson’s product-moment correlation coefficient.
All statistical tests in this study were considered significant at P < 0.05 and were 2 tailed.
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